Table 1 Clinical trials on the effects of hyperoxia in intensive care and emergency medicine
Study acronym | Trial no. | Patient condition | Intervention | Primary outcome measures | Planned enrolment |
|---|---|---|---|---|---|
OXYGEN-ICU | NCT01319643 | ICU treatment for 3 days | FiO2 titrated to SpO2 94–98/PaO2 70–100 mmHg vs. SpO2 >97 %/PaO2 100–150 mmHg | Mortality day 30 | Terminated at n = 434 (slow recruitment) |
HYPER2S | NCT01722422 | Septic shock | FiO2 titrated to SpO2 88–95 % vs. FiO2 = 1.0 over the first 24 h | Mortality day 28 | Terminated at n = 442 |
AVOID | NCT01272713 | Acute myocardial infarction | Air (unless SpO2 <94 %) vs. 8 L/min O2 during pre-hospital phase, thereafter according to hospital protocol | Infarct size, time course of CK-MB and cTnI | Completed at n = 638 |
DETO2X-AMI | NCT01787110 | Acute coronary syndrome | Air (unless SpO2 <90 %) vs. 6 L/min O2 over 6–12 h | Mortality at 1 year | 6600 |
BRAINOXY | NCT01201291 | TBI, GCS ≤8 | FiO2 0.4 vs. 0.7 | GOS/GOSE at 6 months | n un-specified; terminated (slow recruitment) |
SO2S | ISRCTN52416964 | Stroke, ICH | Air vs. 2 (SpO2 >93 %)/3 L/min overnight vs. 2 (SpO2 >93 %)/3 L/min continuously until day 3 | Modified Rankin scale at day 90 | Completed at n = 8003 |
REOX | NCT01881243 | Cardiac arrest | Observational study; association between hyperoxia and outcome | Blood isofuranes/-prostanes | 133 |